Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChemoID-guided Chemotherapy in Recurrent GBM
NCT03632135Phase 3Completed
- Sponsor
- Cordgenics LLC
- Start
- May 2018
- Primary completion
- Jun 2022
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial (2 arms), sponsored by Cordgenics LLC. Primary endpoint: Median Overall Survival at 36 months. Started May 2018; status: completed.
Beyond the preview
Go deeper on NCT03632135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03632135.